GET DAILY SIGNALSAlignment Healthcare (ALHC) Reports Strong +36.7% Revenue Growth but Cuts Full-Year Outlook
Key Takeaways
- Third quarter 2026 revenue rose 36.7% year over year to about $1.36 billion, topping the roughly $1.31 billion consensus estimate.
- GAAP EPS came in at -$0.04, in line with consensus but a reversal from a $0.02 profit in the same quarter last year.
- Adjusted EBITDA of about $21.8 million slightly missed expectations, and management cut its full-year EBITDA outlook.
- Health plan membership reached 301,200, up from 294,100 in the prior quarter, driven by continued demand.
- Management cited higher-than-expected medical cost trends, including inpatient and skilled nursing facility costs, as a key headwind.
- Shares traded lower in after-hours activity following the report and the reduced full-year guidance.
Why This Earnings Report Matters
Alignment Healthcare, a California-based Medicare Advantage insurer, entered this report under pressure. The company had posted a profitable second quarter, but sentiment soured sharply in October after CMS released 2027 star ratings that analysts believe downgraded the company's largest contract from 4.0 to 3.5 stars, threatening quality bonus payments. Several analysts also flagged near-term headwinds from acute hospital billing and skilled nursing facility costs. Against that backdrop, investors were closely watching whether medical cost trends would validate those concerns and how management would frame its 2027 strategy, making this quarterly earnings release a critical test of the company's growth story. I also checked this using Tickeron’s AI Screener to see how ALHC compares to others in the industry.
Breaking Down the Numbers
For the third quarter ended September 30, 2026, Alignment Healthcare reported total revenue of roughly $1.36 billion, up 36.7% year over year and above the consensus estimate of about $1.31 billion. GAAP EPS was -$0.04, in line with consensus but down from a $0.02 profit a year earlier. Net loss attributable to the company was approximately $8.1 million, compared with net income of about $3.7 million in the prior-year quarter.
Adjusted EBITDA of approximately $21.8 million narrowly missed the roughly $22.3 million consensus, reflecting higher medical expenses. The company guided fourth quarter revenue to a midpoint of about $1.32 billion, slightly below the consensus of about $1.33 billion, and lowered its full-year EBITDA guidance to a midpoint of roughly $100 million, well below the consensus of about $147.8 million. Membership grew to 301,200 members, up from 294,100 in the second quarter.
How the Market Reacted
The stock traded lower in after-hours activity following the report, as the revenue beat was overshadowed by reduced forward guidance and the lingering star-ratings overhang. Sentiment had already deteriorated sharply entering the quarter, with several analysts downgrading the stock and cutting price targets after the CMS star-ratings release. The combination of softer fourth-quarter revenue guidance, a significantly lower full-year EBITDA outlook, and management's acknowledgment that medical trends ran higher than expected reinforced investor caution about near-term profitability. From what I see, this reaction highlights how guidance revisions can outweigh solid top-line results in the near term.
What to Watch Going Forward
Management framed the guidance reduction as a prudent response to current headwinds, noting that the revised outlook does not assume any benefit from ongoing corrective actions. Chairman and CEO John Kao emphasized execution as the immediate priority, stating the company is confident it can deliver against the lowered expectations.
Investors will be watching several factors in the months ahead. First, the persistence of utilization pressures—particularly inpatient admissions and skilled nursing facility costs—will be critical in determining whether the cost headwinds are temporary or structural. Second, the company's legal challenge to the 2027 star-ratings downgrade remains a key uncertainty, given that a favorable outcome could restore quality bonus payments that analysts estimate carry a significant future earnings impact.
Third, the company's 2027 strategy and any mitigation efforts, including shared risk arrangements and potential benefit adjustments, will be closely scrutinized as bids for the coming plan year take shape. Finally, ongoing membership growth and the company's expansion into new markets will indicate whether demand momentum can offset margin pressures. The next several quarters will test whether Alignment Healthcare can contain costs while sustaining its rapid growth trajectory. I’m watching this closely for signs of stabilization.
AI Tools in My Research Process
When evaluating earnings momentum and shifting sentiment around names like ALHC, I often turn to Tickeron’s AI Screener to filter the market efficiently. This tool helps me scan for technical patterns, fundamentals, and AI-driven signals across thousands of stocks and ETFs, making it easier to identify relevant opportunities and compare peers without manual effort. It has become a regular part of how I cross-check ideas and surface broader market context.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALHC's RSI Indicator ascends from oversold territory
The RSI Indicator for ALHC moved out of oversold territory on October 05, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In 27 of the 31 cases the stock moved higher. This puts the odds of a move higher at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 54 cases where ALHC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for ALHC just turned positive on October 02, 2026. Looking at past instances where ALHC's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.
Following a +3.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALHC advanced for three days, in 249 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 26, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALHC as a result. In 67 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALHC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for ALHC entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. ALHC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ALHC's P/B Ratio (6.306) is slightly higher than the industry average of (3.425). P/E Ratio (40.300) is within average values for comparable stocks, (120.437). ALHC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.389) is also within normal values, averaging (0.569).
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALHC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ManagedHealthCare
Advertisement